Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Dried Blood Spot Collection for AQP4-IgG testing provides opportunity for improving global health NMOSD diagnostics
Autoimmune Neurology
S50 - Autoimmune Neurology: NMOSD (3:30 PM-3:42 PM)
001

NMOSD is a devastating inflammatory CNS disease that results in blindness and paraplegia if left undiagnosed and untreated. It is most frequent in Asian and African populations. Access to testing and treatment is extremely limited in developing nations. Blood collected and dried on a paper card (dried blood spot [DBS]) offers a cost-effective simple method for collecting, preserving, and transporting blood specimens in settings with minimal infrastructure. 

To assess the sensitivity, specificity, and stability of AQP4-IgG detection in DBS. 

Patients with known AQP4-IgG seropositivity used lancets to draw blood from their index fingers and placed approximately 1mL on Whatman® 903 Protein Saver Cards that were either collected in clinic or mailed in the Mayo Clinic Neuroimmunology Laboratory for AQP4-IgG testing on a live-cell cell-binding assay using HEK293 cells transfected with AQP4-expressing plasmid and tested by flow cytometry (gold standard for AQP4-IgG detection). A 13 mm punch, corresponding to 80 uL of blood from the DBS, was soaked in 200 uL of LCBB overnight to extract the antibodies from the paper and were then tested for AQP4-IgG detection. Disease Control samples were also tested.

30 AQP4-IgG+ NMOSD patients provided DBS. Fifteen had DBS and serum collected at the same time, 13 (87%) of the DBS tested positive. The remaining 15 patients sent the DBS by mail: 13 (87%) of the DBS tested positive (no concurrent serum sample, previously tested positive). DBS at room temperature analyzed at 3 (n=5) and 9 months (n=4) demonstrated AQP4-IgG positive results in all cases. All DBS from 50 disease control (including MOG-IgG positive samples) were negative.

DBS has a sensitivity of 87% compared with serum for AQP4-IgG detection. The positive signal persisted despite storage at room temperature for up to 9 months.  DBS collection holds promise to improve access to AQP4-IgG testing and NMOSD diagnosis worldwide.

Authors/Disclosures
Yahya J. Abdulrahman
PRESENTER
Mr. Abdulrahman has nothing to disclose.
James Fryer James Fryer has received intellectual property interests from a discovery or technology relating to health care.
Vyanka Redenbaugh, MB BCh BAO (Mayo Clinic) Dr. Redenbaugh has nothing to disclose.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Jessica A. Sagen (Mayo Clinic) Ms. Sagen has nothing to disclose.
No disclosure on file
John Chen No disclosure on file
Anastasia Zekeridou, MD, PhD, FAAN (Neuroimmunology Laboratory, Mayo Clinic) The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.
Andrew McKeon, MD (Mayo Clinic) The institution of Dr. McKeon has received research support from National Institutes of Health. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received publishing royalties from a publication relating to health care.
John R. Mills, MD, PhD (Mayo Clinic) The institution of Dr. Mills has received research support from Werfen Diagnostics. Dr. Mills has received intellectual property interests from a discovery or technology relating to health care.
Sean J. Pittock, MD (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech, Inc.. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Therapeutics, Inc.. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prime Therapeutics. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedImmune/Viela Bio. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB, Inc. Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman/LaRoche AG. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hofman/LaRoche. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. The institution of Dr. Pittock has received research support from Grifols. The institution of Dr. Pittock has received research support from NIH. The institution of Dr. Pittock has received research support from Viela Bio/MedImmune/Horizon. The institution of Dr. Pittock has received research support from Alexion Pharmaceuticals. The institution of Dr. Pittock has received research support from F. Hoffman/LaRoche/Genentech. The institution of Dr. Pittock has received research support from NovelMed. The institution of Dr. Pittock has received research support from AstaZeneca. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.